IL-SHIPPEO
Shippeo has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Real-Time Transportation Visibility Platforms. The global multimodal shipment visibility platform was also recently named a Customers’ Choice by Gartner® in the October 2023 Gartner Peer Insights™ “Voice of the Customer”: Real-Time Transportation Visibility Platforms report, scoring the highest customer recommendation willingness rate of all providers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240402784237/en/
(Graphic: Shippeo)
“We are delighted to be recognized as a Leader in this latest Gartner research,” says Shippeo CEO & co-founder, Pierre Khoury. “We are also deeply thankful for the support of our wonderful customers and ecosystem partners, and incredibly proud of our talented teams. As the real-time transportation visibility (RTTV) market continues to mature in North America, Europe, and increasingly across APAC, companies are realizing the significant value visibility brings. From increasing customer NPS with more premium delivery experiences, to reducing operating costs, optimizing processes and cash flow, and monitoring and reducing carbon emissions, our platform is being recognized as an important enabler of next-generation supply chains.”
Strong growth and market momentum in North America, Asia Pacific and Europe
Over the past two years, the company’s customer base tripled. In 2023, the North American revenue grew 153% year over year, with 25% of all new revenue generated having come from companies in this region switching to Shippeo from another provider. Notable new North American customers include Amazon, Barilla, and Palermo Villa, Inc. (dba Palermo’s Pizza). The company also significantly grew its customer base in Asia Pacific, welcoming some of the region’s most recognizable brands, including Yamaha Motor. Notable customers joining in other parts of the world include Arlanxeo, Birra Peroni, DP World, Evonik, Fujifilm and Hartmann Group.
“Our approach to visibility with a greater focus on data quality and customer support has resonated extremely well with the RTTV market in North America,” says Lucien Besse, COO & co-founder at Shippeo. “Since 2020, our partnership with e2open has blossomed into a powerhouse collaboration. Through close cooperation and a shared commitment to excellence, we've achieved remarkable success together, in North America and abroad. This enduring partnership underscores our collective ability to innovate and thrive in today's dynamic landscape.”
Global multimodal visibility network
With established regional head offices in Chicago for the Americas, Singapore for APAC, and Paris for Europe, Shippeo’s network now tracks more than 50 million shipments a year across all modes, in more than 130 countries on six continents, with a 258,000-strong carrier network. Their ocean visibility network covers 99% of the world’s containerships thanks to integrations with major shipping lines. The company’s partner network has also enjoyed continued momentum, now comprising over 1000 system integrations with TMS, WMS, ERPs and telematics devices, representing a 30% increase since the start of 2022. Key strategic partners include e2open, SAP, Infor, Tesisquare, Alpega, Oracle, Siemens, Google, Snowflake, Microsoft, and BlueYonder.
The most recommended provider for three years running
Shippeo has had the highest recommendation rate of all providers on Gartner Peer Insights for over three years. In October 2023, the company was positioned in the Customers’ Choice Quadrant, having scored a 96% recommendation rate, the highest of all providers (based on 116 reviews as of August 2023).
Disclaimer:
GARTNER is a registered trademark and service mark and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
Gartner “Magic Quadrant for Real-Time Transportation Visibility Platforms 2024” by Carly West, Oscar Sanchez Duran, and Nathan Lease, 26 March 2024.
Gartner, “Voice of the Customer for Real-Time Transportation Visibility Platforms”, by Peer Contributors, 31 October 2023.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular Purpose.
Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more resilient, sustainable, and customer-centric supply chains. This is made possible with highly accurate real-time operational visibility and Transport Process Automation™ to streamline transportation processes, reduce latency and improve operational efficiency. Their Multimodal Visibility Network integrates with more than 1,000 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Ahold Delhaize, AkzoNobel, Amazon, Avery Dennison, Arlanxeo, Barilla, Birra Peroni, Bosch Siemens Hausgeräte, Carrefour, Coca-Cola HBC, DP World, Evonik, Fujifilm, Jaguar Land Rover, Hartmann Group, Heineken, Kuehne+Nagel, L’Oréal, LVMH, Renault Group, Sabic, Saint-Gobain, XPO Logistics and Yamaha Motor, trust Shippeo to track more than 50 million shipments per year across 130 countries. Learn more at www.shippeo.com, LinkedIn, Facebook, X (formerly Twitter)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402784237/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom